Mucormycosis infection in patients with COVID-19: A systematic review

SeyedAhmad SeyedAlinaghi1 | Amirali Karimi2 | Alireza Barzegary3 | Zahra Pashaei4 | Amir Masoud Afsahi4 | Sanam Alilou2 | Nazanin Janfaza5 | Alireza Shojaei3 | Fatemeh Afroughi3,6 | Parsa Mohammadi2 | Yasna Soleimani3 | Newsha Nazarian3 | Ava Amiri1 | Marcarious M. Tantuoyir2,7 | Shahram Oliaei8 | Esmaeil Mehraeen9 | Omid Dadras10

1Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
2School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3School of Medicine, Islamic Azad University, Tehran, Iran
4Department of Radiology, School of Medicine, University of California, San Diego (UCSD), San Diego, California, USA
5Internal Medicine Department, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
7Biomedical Engineering Unit, University of Ghana Medical Center (UGMC), Accra, Ghana
8HBOT Research Center, Golestan Hospital, Islamic Republic of Iran, Navy and AJA Medical University, Tehran, Iran
9Department of Health Information Technology, Ardebil University of Medical Sciences, Ardebil, Iran
10Department of Global Health and Socioepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Abstract

Introduction: Several reports previously described mucormycosis co-infection in patients with COVID-19. As mucormycosis and COVID-19 co-infection might adversely affect patients' outcomes, we aimed to systematically review the related evidence and the subsequent outcomes.

Methods: We conducted a systematic review of relevant articles searching the keywords in the online databases of PubMed, Scopus, Embase, Cochrane, and Web of Science. All the records from the start of the pandemic until June 12th, 2021 underwent title/abstract and then full-text screening process, and the eligible studies were included. We did not include any language or time restrictions for the included studies.

Results: We found 31 eligible studies reporting 144 total cases of COVID-19 and mucormycosis co-infection. The nose, cranial sinuses, and orbital cavity were the most commonly involved organs, although the cerebrum, lungs, and heart were also involved in the studies. Pre-existing diabetes mellitus (DM), as well as corticosteroid use, were the most commonly identified risk factors, but other underlying conditions and immunomodulatory drug use were also present in several cases. Aspergillus was
the most commonly reported micro-organism that caused further co-infections in patients with concurrent COVID-19 and mucormycosis. As most of the studies were case reports, no reliable estimate of the mortality rate could be made, but overall, 33.6% of the studied cases died.

Conclusion: Early diagnosis of mucormycosis co-infection in COVID-19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co-morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co-infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients.

KEYWORDS
- black fungus
- COVID-19
- mucormycosis
- SARS-CoV-2

1 | INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic emerged as a new health crisis worldwide and affected millions of people.1-4 COVID-19 causes several symptoms and can precipitate severe multi-organ involvements, acute respiratory distress syndrome (ARDS), and death.5-7

Cases of bacterial or fungal co-infections or super-infections have been reported in previous studies and can increase the mortality rates and complications of COVID-19.8,9 Several reports of COVID-19 and mucormycosis co-infection exist.10 Although antibiotics and systemic corticosteroids could reduce the risk of severe COVID-19 complications and bacterial co- or super-infection, they can provide a favorable condition for opportunistic infections, such as mucormycosis.11-13

Mucormycosis, also commonly known as the disease caused by the black fungus, is a rare and life-threatening fungal infection with various ranges of involvement.14,15 A previous systematic review reported an enormous 33.6% mortality rate in patients co-infected with mucormycosis and COVID-19.16

This potentially deadly black fungus can affect various organs and systems.14,15 Rhino-orbital, pulmonary, oral, cerebral, sinonasal, and gastrointestinal mucormycosis are some of the sites of involvement in mucormycosis.9,17,18 Underlying diseases such as poorly controlled diabetes mellitus (DM), hematological malignancies, or immunocompromised state are predisposing factors to mucormycosis infection.9,19,20

Early diagnosis and treatment can reduce the mortality rate and improve the outcome. Understanding this condition may improve the diagnosis and quality of care of the COVID-19 patients co-infected with mucormycosis. Therefore, we aimed to systematically review mucormycosis co-infection in patients with COVID-19 and its subsequent outcomes. This systematic review was conducted to establish the risk factors for mucormycosis co-infection in patients with COVID-19, the target organs for mucormycosis in the co-infected patients, the diagnosis time between the COVID-19 and mucormycosis infection, the provided treatments and the mortality of the co-infected patients, and other further co-infections in the patients co-infected with COVID-19 and mucormycosis.

2 | METHODS

This is a comprehensive review to shed light on the incidence of fungus mucormycosis in COVID patients based on the current evidence. To authenticate the end results this investigation benefits from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

2.1 | Search strategy

We systematically searched the keywords in the online databases of PubMed, Scopus, Embase, Web of Science, and Cochrane and extracted all relevant publications and reports from December 2019 to June 12th, 2021. All the searches were conducted as title/abstract, in all the databases, and PubMed is mentioned as an example in the query below:

A. [COVID-19] OR [SARS-CoV-2] OR [SARS-CoV2] OR [2019-nCoV] OR [Novel coronavirus]

B. [Mucormycosis] OR [Mucormycose] OR [Mucorales] OR [Black fungus]

C. [A] AND [B]

2.2 | Study selection

We aimed to include the original studies that reported mucormycosis co-infection in patients with COVID-19. We downloaded the records into the EndNote software and then excluded the duplicate records using the software. Then, the remaining duplicates were excluded manually and the records got ready to
enter the two-phase screening process. To select and include pertinent literature, two of our research staff read and selected the eligible studies based on their titles and abstracts. At the next step, we inspected the full texts of these studies carefully, and finally, the studies that adhered to the inclusion criteria were included in the qualitative synthesis.

2.3 | Inclusion/exclusion criteria

Original studies published in any language that met the aim of our study, that is, those including COVID-19 patients with confirmed or suspected mucormycosis co-infection, were included. We did not include any language or time restrictions for the included studies. We included all the peer-reviewed original studies, case reports and case series.

The exclusion criteria for this study were as follows:

1. Non-original studies, such as reviews, systematic reviews, meta-analyses, or editorials without original reports.

2. Studies lacking available full texts, such as abstracts and conference abstracts.

3. Any pure laboratory or animal studies without mentioning human subjects.

4. Patients with mucormycosis that did not have previously suspected or diagnosed COVID-19, that is, sole mucormycosis without co-infection.

2.4 | Data extraction

After summarizing the literature, two independent investigators assembled and transferred the relevant information and findings including first author (reference) information, study type (eg, original article), country of origin, study population (N), patient mean age, male proportion, comorbidities, affected organ, day of mucormycosis detection after preliminary COVID-19 diagnosis, other opportunistic and bacterial co-infection, treatments received (for COVID-19 and mucormycosis), mortality rate, and summary of findings into a table.
| Author (reference) | Type of study | Country | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|-------------------|---------------|---------|----------------------|----------|--------------|---------------|---------------|-----------------------------------------------|-------------------------------------------------|-------------|---------------------|
| Alekseyev et al  | Case report   | USA     | 1 patient            | 41       | 100%         | Type 1 diabetes mellitus (DM), hypertension, coronary artery disease | Heart, lungs, palate | — | Steroids, hydroxychloroquine, Intravenous (IV) fluids, cefepime, amphotericin B, IV heparin, sphenoidotomy, and ethmoidectomy maxillary antrostomy | 0% | The severity of mucormycosis infection is due to its rapid disease progression and angi-invasive character |
| Arana et al      | Case report   | Spain   | 2 patients           | 55       | 100%         | Type 2 DM (n = 1), hypertension (n = 2), end-stage renal disease with kidney transplant (n = 2), hypothyroidism (n = 1), ischemic heart disease (n = 1) | Respiratory system | 7 and 21 days | Dexamethasone, prednisone, ceftriaxone, hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, liposomal amphotericin B, isavuconazole, posaconazole, maxillectomy, mechanical ventilation | 0% | — |
| Ashour, Manar et al | Case series  | Egypt   | 8 patients           | 53.6     | 62.5         | DM type 2 (n = 6), chronic kidney disease (n = 2), hyperlipidemia (n = 2), hypertension (n = 2), hypothyroidism (n = 1), ischemic heart disease (n = 1), cerebral infection (n = 1) | Respiratory system, orbital cavities, ethmoidal and maxillary sinuses, nasal cavity, nasopharynx, carotid artery, hard palate, skin | 14 days | Aspergillosis (12.5%) | Amphotericin B, ambisome, itraconazole, surgical debridement, orbital enucleation, mechanical ventilation | 37.5% | — |
| Bayram et al     | Prospective observational study | Turkey | 11 patients with rhino-orbital mucormycosis | 73.1     | 81.8%        | Uncontrolled DM type 2 (n = 9), acute and chronic renal failure (n = 5), coronary artery disease (n = 2), chronic obstructive pulmonary disease (n = 1), myelodysplastic syndrome (n = 1), hyperthyroidism (n = 1), atrial fibrillation (n = 1) | Paranasal sinuses, orbital cavities | Mean of 14.4 days | Amphotericin B, voriconazole, surgical debridement, mechanical ventilation | 63.6% | The risk of coinfections in patients with acute respiratory distress syndrome (ARDS) receiving broad-spectrum antibiotics, corticosteroids, and supported by invasive or non-invasive ventilation is higher |
| Bellanger et al  | Case report   | France  | 1 patient            | 55       | 100%         | Follicular lymphoma | Lungs | 20 days | Aspegillar fungicidal and RNazoprimicronopsi, Cytomegalovirus (CMV) and HHV6 viremia | Amphotericin B, mechanical ventilation | 100% | A hematologic malignancy was independently associated with high SARS-CoV-2 viral load and the SARS-CoV-2 infection itself may induce an immunosuppressive state exposing the patient to invasive mold disease |
| Author (reference) | Type of study | Country | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Co-infection | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|-------------------|--------------|---------|----------------------|----------|--------------|---------------|---------------|-----------------------------------------------|-------------|---------------------------------------------------|--------------|---------------------|
| Buil et al \(^{24}\) | Case series  | The Netherlands | 4 patients | 65.2 | 100% | DM (n = 2), chronic lymphocytic lymphoma (n = 1), Obesity (n = 1) | Lungs, rhino orbital cavity, kidney, sinus, eye, cranium | 17 days | Rhizopus microsporus, L. ramoosa, A. fumigatus, R. oryzae | Tocilizumab, dexamethasone, prednisone, amphotericin B, posaconazole, voriconazole, isavuconazole, surgical debridement, interferon-γ, mechanical ventilation | 75% | – |
| Dallalzadeh et al \(^{17}\) | Case report | USA | 2 patients | 42 | 100% | Type 2 DM (n = 2) | Cranium, sinonasal cavity, orbit, lungs, | 6 days | Rhizopus | Lateral canthotomy, IV amphotericin, isavuconazole, micafungin, remdesivir, dexamethasone, surgical debridement, | 50% | – |
| do Monte et al \(^{18}\) | Case report | Brazil | 1 patient | 86 | 100% | Arterial hypertension | GI system, respiratory system, blood, | – | – | Ceftriaxone, azithromycin, oseltamivir, hydrocortisone, vasopressors, mechanical ventilation, red blood cells units, omeprazole | 100% | Depending on the anatomic site involved, mucormycosis can present as a variety of different syndromes, including rhino-orbital-cerebral, pulmonary, cutaneous, and less often GI, renal, and disseminated diseases |
| El-Kholy et al \(^{21}\) | Longitudinal prospective study. | Egypt | 36 patients | 52.92 | 52.8% | DM (n = 10), hypertension (n = 6), uncontrolled leukemia (n = 1), pancreatic cancer (n = 1), CKD (n = 3), asthma (n = 3), cardiac (n = 1), hypothyroidism (n = 1), systemic lupus erythematosus (n = 2) | Sinonasal cavity, cerebrum, orbit, palate, skin | 1782 days | Aspergillus species (30.6%) | Amphotericin B, voriconazole. posaconazole, surgical debridement, mechanical ventilation | 36.1% | – |
| Fekkar et al \(^{23}\) | Case report | France | 2 patients with probable/putative invasive pulmonary aspergillosis and mucormycosis co-infection | 62.5 | 100% | Obesity (n = 2), kidney transplantation (n = 1), hypertension (n = 1), dyslipidemia (n = 1) | Lungs | Not mentioned, diagnosis made 3 and 21 days after ICU admission | Both patients had invasive pulmonary aspergillosis co-infection | One had no specific antifungal or COVID-19 treatments (died later). One received no specific COVID-19 therapies, but voriconazole, amphotericin B, caspofungin, and isavuconazole for fungal infections (alive) | 50% | The risk of pulmonary fungal infection is low in the COVID-19 patients without underlying immunosuppression |
| Garg et al \(^{24}\) | Case study | India | 1 patient | 55 | 100% | Type 2 DM, hypertension, ischemic cardiomyopathy, end-stage renal disease, severe anemia | Intestinal opacities, heart, lungs | 3 | Escherichia coli, Aspergillus fumigatus | IV dexamethasone, remdesivir, O₂ supplement thrumophoprophylaxis, maintenance hemodialysis, liposomal amphotericin B, right upper lobectomy | 0% | For critically diagnosed COVID-19 patients, doctors must be aware of serious infections that can complicate the course of COVID-19. A high degree of clinical suspicion is required to diagnose pulmonary mucormycosis. Early diagnosis and timely management are completely necessary to improve outcomes in pulmonary mucormycosis |

(Continues)
| Author (reference) | Type of study | Country | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Co-Infection | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|--------------------|---------------|---------|----------------------|---------|--------------|---------------|----------------|---------------------------------------------|-------------|-----------------------------------------------|--------------|-------------------------------|
| Hanley et al \(^{15}\) | Cohort study/ case series | UK | 10 patients | 73 | 70% | Not available | Hilar lymph nodes, heart, brain, lungs (DAD), pancreas | 4 patients on ventilator | 100% | IV ceftriaxone, amphotericin, miconazole, and remdesivir | | Invasive secondary mucormycosis was confirmed by Mucorales-specific PCR in one patient during the autopsy. He was a 22-year-old man with necrotic hemorrhagic pancreatitis and no fungal hyphae in his pancreas. Suggesting all human fungal pathogens can complicate COVID-19-associated infections |
| Johnson et al \(^{20}\) | Case report | USA | 1 patient | 79 | 100% | Diabetes, hypertension | Lungs, brain | 19 | Aspergillosis, methicillin-resistant Staphylococcus aureus, Klebsiella pneumoniae | | 0% | The combined risk factors of DM, COVID-19, and recent corticosteroid treatment contributed to both mucormycosis and aspergillosis infections in the patient |
| Kanwar et al \(^{25}\) | Case reports | USA | 1 patient | 56 | 100% | End-stage renal disease | Lungs | 16 | Vancomycin-resistant Enterococcus spp., Bacteroides fragilis | | 100% | In this patient, receipt of two commonly used immunosuppressants likely contributed to mucormycosis risk, suggesting the need for vigilance in hospitalized patients with COVID-19. He was readmitted 5 days after his discharge (16 days after initial positive SARS) with shortness of breath, fatigue, and hemoptysis, which lead to the diagnosis of both mucormycosis and rhizopus infections. On day 17, the patient developed a cardiac arrest and died |
| Karimi-Goloughi et al \(^{26}\) | Case reports | Iran | 1 patient | 61 | 0% | None | Facial nerve, eyes, skin, nose, sinus | 21 | Remdesivir, interferon alpha, systemic corticosteroid, insulin, systemic anti-fungal | | 0% | Invasive mucormycosis was noted in one patient (PMS, Figure 1) and confirmed with Mucorales-specific PCR. The mucormycosis was vasculocentric and disseminated, involving the hilar lymph nodes, heart, brain, and kidney in the same patient. Macroscopic (two [22%] of nine patients) and microscopic (eight [89%] of nine pulmonary thromboemboli) were frequent observations. Invasive mucormycosis was noted in one patient (PMS, Figure 1) and confirmed with Mucorales- |
| Author (reference) | Type of study | Country | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Co-infection | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|--------------------|---------------|---------|----------------------|----------|--------------|---------------|---------------|-----------------------------------------------|--------------|-------------------------------------------------|--------------|-------------------|
| Khatri et al. | Case reports | USA | 1 patient | 68 | 100% | CAD/heart transplant, diabetes type II, hypertension, chronic kidney disease, obstructive sleep apnea | Lungs, GI tract, brain, joints, chest wall, right axilla | 90 | Morganiellomorgani, Enterobacter cloacae, vancomycin-resistant Enterococcus fecium bacteraemia, multiresistant Klebsiella veronii, coagulase-negative Staphylococcus bacteraemia, clindamycin-resistant E. faecium | Oral hydroxychloroquine, amiodarone IV, vancomycin and meropenem, debridement and surgery of sternal wound, mechanical ventilation, cyclosporine, nystatin, tracheostomy, omental flap, split thickness skin graft, IV L-AmB, resection of subclavian artery, infected prosthetic graft | 100% | We describe a case of mucormycosis occurring after COVID-19, in an individual who received a recent heart transplant for severe heart failure and was diagnosed with COVID-19 2 months later. Approximately 3 months after the COVID-19 diagnosis, he developed cutaneous mucormycosis at an old intravascular device site. He underwent extensive surgical interventions, combined with broad-spectrum antifungal therapy. Despite a lot of aggressive therapeutic measures, he died after a prolonged (175 days) hospital stay. |

Specific PCR. The mucormycosis was vasculocentric and disseminated, involving the hilar lymph nodes, heart, brain, and kidney in the same patient. Macroscopic (two [23%] of nine patients) and microscopic (eight [89%] of nine) pulmonary thromboemboli were frequent observations. The new-onset glucocorticoid-induced diabetes and immunosuppression by steroids may have predisposed this patient to invasive mucormycosis. There may be a contribution by COVID-19, which was present at the time of readmission, to susceptibility to mucormycosis. Clinicians should be familiar with the manifestation of invasive mucormycosis in patients with COVID-19 who received corticosteroids during the pandemic.
| Author                      | Type of study | Country | Study population (N) | Sex | Male no. (%) | Comorbidities                                                                 | Affected organ                                                                 | Day of mucormycosis detection after COVID-19 diagnosis | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|-----------------------------|---------------|---------|----------------------|-----|--------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|---------------|----------------------|
| Sai Krishna et al.          | Case reports  | India   | 2 patients           | 42  | 100%         | Type 2 DM (n = 2); hypertension (n = 1)                                        | Midface, 1/4 teeth maxillary sinus and bone, zygomatic bone                  | 60                                                      | Insulin, IV L-AmB, surgical resection, itraconazole, extraction of URQ teeth, posaconazole | 0%            | COVID-19 patients are predisposed to developing various fungal infections during the course and in later stages of this disease, especially severely ill cases, due to a decrease of CD4+ T cells and CD8+ T cells leading to immune suppression. So the main objective of this case report is to document cases of oral and maxillofacial pathologies which are associated with COVID-19 infection. |
| Krishna et al.              | Case reports  | UK      | 1 patient            | 22  | 100%         | Hypothyroidism, steatohepatitis, thrombo-embolic disease                      | Lungs, heart, hilar nodes, brain, pharynx, nasal mucosa, trachea             | Pericarditis                                            | Mechanical ventilation, aspirin, LMW-heparin, hydroxychloroquine, azithromycin, meropenem, telipalmin, argatroban, noradrenaline, vasoressin, gentamicin, tracheostomy, bronchoalveolar lavage | 100%          | A young obese Asian male was admitted with an acute anterior cerebral artery (ACA) territory infarct and severe COVID-19 pneumonia to the ICU. He had a complicated stay with recurrent episodes of vasoplegic shock and multiorgan dysfunction. At autopsy, he was confirmed to have disseminated mucormycosis. In our belief, this is the first documented case of disseminated mucormycosis in an immunocompetent host with COVID-19. The lack of modalities and biomarkers to diagnose mucormycosis, along with the extremely high morbidity in untreated cases, present a unique challenge to clinicians dealing with critically ill COVID-19 patients. |
| Maini et al.                | Case reports  | India   | 1 patient            | 38  | 100%         | None                                                                          | Lungs, eye, maxillary and ethmoidal sinus                                    | 18                                                      | IV remdesivir, methylprednisolone, desamethasone, FESS surgery, methronidazole, fluconazole, tocolzumab, tobramycin, nebulized lateral canthotomy, inferior cantholysis, monocel | 0%            | The patient was diagnosed with COVID-19 and treated according to the persisting protocols. Following recovery, the patient developed chemosis and pain in the left eye. A diagnosis of mucormycosis was established after MRI and FESS. Initially, conservative management was done and later on surgical debridement. The patient recovered with minimal residual deformity after 38 days hospitalization. |
| Author (reference) | Type of study | Country | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Co-infection | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|-------------------|---------------|---------|---------------------|----------|--------------|---------------|----------------|-----------------------------------------------------|--------------|--------------------------------------------------|--------------|----------------------|
| Mehta et al^11     | Case report   | India   | 1 patient           | 60       | 100%         | DM            | Lungs, eye, midface, sinuses | 11                     | —                        | Meropenem, oseltamivir, methylprednisolone, dexamethasone, enoxaparin, ventilator, tocolimusab, sitagliptin/metformin, topical moxifloxacin, vancomycin, L-AmB, steroid therapy | 100%        | Extensive use of steroids and monoclonal antibodies, also broad-spectrum antibiotics may lead to the development or exacerbation of pre-existing fungal diseases. Physicians should be aware of the possibility of secondary invasive fungal infections in COVID-19 patients, especially in patients with existing risk factors. It should enable early diagnosis and treatment with the subsequent reduction of mortality and morbidity. The use of therapeutic agents should be monitored to achieve the effect at the lowest dose and shortest duration. The use of broad-spectrum antibiotics, especially in the absence of infection, should be re-evaluated. |
| Mekonnen et al     | Case report   | USA     | 1 patient           | 60       | 100%         | Diabetes, asthma, hypertension, hyperlipidemia | Lungs, eye, sinuses, nerve | 24                     | Angioinvasion | Remdesivir, intranasal biopsy and endoscopy, vancomycin, ceftazidime, L-AmB, caspofungin, dexamethasone, convalescent plasma, endoscopic debridement, posaconazole | 100%        | Acute invasive fungal rhinosinusitis is a rare but highly morbid infection, primarily affecting immunosuppressed individuals. The same is at particularly high risk of complications and mortality in the setting of coronavirus-related ARDS. The authors present a case of acute invasive fungal rhino-orbital mucormycosis in a patient with COVID-19. Prompt recognition, initiation of therapy, and consideration of the challenges of rapidly evolving COVID-19 therapy guidelines are important for improving patient survival |
| Rao et al^22       | Case report   | India   | 1 patient           | 66       | 100%         | Poorly controlled diabetic | Eyes                  | 12                     | —                        | Systemic steroids for COVID-19, functional endoscopic sinus surgery, IV liposomal amphotericin | 0%           | The patient had orbital infarction syndrome secondary to rhino-orbital mucormycosis |
| Ravani et al^23    | Retrospective cohort | India | 31 patients | 56.3 years | 64.5% (n = 30), Hypertension (n = 17), Ischemic heart disease (n = 1), Kidney disease (n = 2) | Uncontrolled diabetes | Eyes | 60                     | —                        | IV liposomal amphotericin in B and debridement of local necrotic tissue | 9.6%        | Rhino-orbital cerebral mucormycosis and HbA1c ≥8 mmol/mol must be treated aggressively |

(Continues)
| Author (reference) | Type of study | Country   | Study population (N) | Mean age | Male no. (%) | Comorbidities | Affected organ | Day of mucormycosis detection after COVID-19 diagnosis | Co-infection | Treatments received (for COVID-19 and mucormycosis) | Mortality rate | Summary of findings |
|-------------------|---------------|-----------|----------------------|----------|--------------|---------------|---------------|-----------------------------------------------------|-------------|-----------------------------------------------------|--------------|---------------------|
| Revannavar, et al | Case report   | Italy     | 1                    | Middle-aged | 0%           | Uncontrolled diabetes | Eyes         | —                                                  | —           | Amphotericin B and antibiotics functional endoscopic sinus procedure | 0%           | Early diagnosis and treatment are essential to prevent further end-organ damage |
| Saldanha et al    | Case report   | India     | 1                    | 32 years | 0%           | Uncontrolled diabetes | Eyes, nose, and paranasal sinus | —                                                  | —           | emergency endoscopic surgery with or without debridement conventional amphotericin B 25 mg/day | 0%           | Should be mindful of the probability of development of fungal infections such as mucormycosis in patients with COVID-19 illness, especially in those with comorbidities and on immunosuppressive agents in the coming future |
| Sarkar et al      | Case report   | China     | 10                   | Middle-aged | Unknown DM (n = 10), DKA (n = 9) | Rhino-orbital | —             | IV desmethylor oral prednisolone in n = 5 | 40%         | Bacterial and fungal coinfections | 40%         | Should be mindful of the probability of development of fungal infections such as mucormycosis in patients with COVID-19 illness, especially in those with comorbidities and on immunosuppressive agents in the coming future |
| Sen et al         | retrospective, interventional study | India | 6                    | 60.5 | 100%      | Type 2 DM (n = 6), Hypertension (n = 3), coronary artery disease (n = 2) | Rhino-oritbo-cerebral | 15.6 | IV desmethylor oral prednisolone in n = 5 | 0%         | The incidence of rhino-orbito-cerebral Mucormycosis is likely to rise, both as a co-infection and as a sequela of COVID-19. Early diagnosis and management with appropriate and aggressive antifungals and surgical debridement can improve survival |
| Veisi et al       | Case report   | Iran      | 2                    | 40-54 | 50%        | DM (n = 1) | Orbit and paranasal sinuses | After 8 days | — | IV remdesivir, tocilizumab, desmethasone for COVID-19 disease (n = 2), endoscopic debridement, IV Amphotericin B for mucormycosis, mechanical ventilation | 50% | Severe immunosuppressive state secondary to diabetic ketoacidosis without previous treatment made the patient susceptible to both severe COVID-19 and mucormycosis |
| Waizel-Haist et al | Case report   | Mexico    | 1                    | 24 | 0%           | Uncontrolled diabetes | Rhino-orbital mucormycosis | — | — | Aggressive surgical debridement and liposomal amphotericin B, mechanical ventilation | 100% | Severe immunosuppressive state secondary to diabetic ketoacidosis without previous treatment made the patient susceptible to both severe COVID-19 and mucormycosis |
| Werthein- Ehrenreich et al | Case report   | USA       | 1                    | 33 | 0%           | Hypertension, asthma | Orbital | — | Sinus debridement and amphotericin B, remdesivir and convalescent plasma for covid-19 | 0% | — |
| Zurl et al        | Case report   | Austria   | 1                    | 53 | 100%        | Myelodysplastic syndrome, obesity | Pulmonary | — | Tocilizumab and high-dose glucocorticoids for covid-19, piperacillin/tazobactam plus linezolid for pulmonary infection | 100% | — |
To avoid duplications and/or overlaps, other investigators double-checked the selected literature as well.

3 | RESULTS

In this study, 162 documents were retrieved using a systematic search strategy. After a primary review of retrieved articles, 94 duplicates were removed. The title and abstract of the remaining articles were reviewed and 19 studies were excluded. After applying the eligibility criteria and full-text check, 18 articles were excluded, and only 31 articles met the inclusion criteria and were included in the final review (Figure 1). These studies were from India (n = 8), USA (n = 7), Iran (n = 2), Egypt (n = 2), France (n = 2), UK (n = 2), Spain (n = 1), Turkey (n = 1), Brazil (n = 1), the Netherlands (n = 1), Italy (n = 1), China (n = 1), Mexico (n = 1), and Austria (n = 1). In total, 144 cases were identified.

The nose, cranial sinuses, and orbital cavity were the most commonly involved organs, although cerebral, lungs, and heart were also reported. Pre-existing DM (in many cases concurrent with diabetic ketoacidosis [DKA]) as well as corticosteroid use were the most commonly identified risk factors, but other underlying conditions and immunomodulatory drug use were also present in several cases. The most common underlying conditions were DM and hypertension, with the prevalence of 89/134 (66.4%) and 46/134 (34.3%) among the studies that reported the underlying conditions, respectively. The period between diagnosis of COVID-19 and mucormycosis ranged from 3 to 90 days in the included studies, with a mean duration of 25.6 ± 21 days.

Aspergillus was the most commonly reported micro-organism that caused further co-infection in the COVID-19 patients with concurrent mucormycosis. This aspergillus co-infection was reported mainly by two studies in Egypt in 30.6% and 12.5% the patients with COVID-19 and mucormycosis (the sample size of these studies were 36 and eight), and four case reports from France (two studies), India, and the United States. Amphotericin B was the most prescribed treatment given in 92% of the patients. As many of the studies were case reports and patients either died or recovered, the mortality rates ranged from 0% to 100% (Table 1). However, overall, 45/134 (33.6%) of the studied patients with COVID-19 and mucormycosis co-infection died (excluding a post-mortem study by Hanley et al).

4 | DISCUSSION

4.1 | Findings outline

Based on the findings from 31 included studies, the mucormycosis co-infection in COVID-19 patients, the infected organs, mortality rate, diagnosis interval, treatment plan, and further co-infections were reviewed. The most commonly affected site of mucormycotic co-infections in COVID patients are the nose, sinuses, and orbits. The mucormycosis co-infection was often diagnosed between 3 and 45 days after COVID-19 diagnosis, with a mean interval of 25.6 days. In addition, a co-infection with a third micro-organism was occasionally reported, mainly with aspergillosis. We found a mortality rate of 45/134 (33.6%). However, as many of the included studies were case reports, the mortality rate was either not reported or described as 0% for those who survived or 100% for those who died due to mucormycosis co-infection; therefore, the mean mortality rate is not reliable. Among the underlying conditions of patients infected with both COVID-19 and mucormycosis, diabetes was the most abundant with 66.4%. The main findings, such as the most commonly affected site and the most important risk factors, were in line with other systematic reviews.

4.2 | Mucormycosis and COVID-19 co-infection

DM was present in an enormous 66.4% of the patients. Several studies have indicated DM and DKA as significant risk factors of mucormycosis in the pre-pandemic era. In India, a multicenter study revealed higher odds of contracting Rhino-orbito-cerebral mucormycosis (odds ratio: 7.55, P = .001) in DM patients. In the post-COVID time, a recent systematic review consisting of 105 cases of COVID-19 with mucormycosis co-infection reported DM and corticosteroid intake in 80% and 76.3% of cases, respectively. Similarly, in another systematic review by John et al DM, corticosteroid intake, and DKA were present in 93%, 88%, and 14.9% of cases, respectively. These findings are consistent with our results, as pre-existing DM and corticosteroid use were present in most included studies. Hypertension was also present in a remarkable 34.3% of the patients; however, this number might be overestimated due to the high prevalence of DM, as hypertension and DM co-exist together in many patients, such as those with metabolic syndrome. Unfortunately, the design of the studies could not yield any possible assessment of whether hypertension is a risk factor for mucormycosis co-infection or not; therefore, more robust studies are required.

COVID-19 can exacerbate pre-existing DM and precipitate DKA in patients, known risk factors for mucormycosis. Hyperglycemic conditions in DM and hyper acidic state in DKA can predispose patients to mucormycosis due to increasing free iron levels, discussed later in the text.

Currently, corticosteroids are the mainstay of treatment in severe COVID-19 patients. They have been shown to effectively increase survival and reduce mortality in COVID-19 patients. However, corticosteroid intake eliminates the phagocytic capability of WBCs, predisposing patients to fungal infections. In addition, new-onset corticosteroid-induced DM or exacerbated previous DM might enhance the growth of mucormycosis.

COVID-19 itself commences a chain of events that might make patients prone to secondary fungal infections, namely mucormycosis. Here are possible mechanisms through which SARS-CoV-2 infection might give rise to mucormycosis susceptibility:

Dramatic decrease in the total number of T-cells including both CD4+ and CD8+ groups in severe cases of COVID-19 causes an immunocompromised state and thus predisposition to mucormycosis.
1. In severe COVID-19 infection, inflammatory markers such as IL-6, IL-2R, IL-10, and TNF-alpha rise and lead to a term called “cytokine storm”. Cytokine storm elevates ferritin levels and reduces iron export. As a result, iron accumulates in the cells. Iron overload causes tissue damage and necrosis, leading to cell death and free iron release into the circulation. A perfect iron-rich environment is ideal for mucormycosis since the fungus needs iron to grow and spread through the body.

2. A study in the UK reported a higher prevalence of DM and DKA in COVID-19 patients than in the general population. The SARS-CoV-2 infection might exhibit new-onset DM features either due to corticosteroid therapy or the disease itself similar to the SARS-CoV-1. Expression of angiotensin-converting enzyme two receptors in pancreatic islets in COVID-19, along with increased insulin resistance due to cytokine storm, might explain the diabetogenic nature of COVID-19. Excessive glucose occupies the iron-binding site of ferritin and transferrin in hyperglycemia. Subsequently, free iron levels and thus mucormycosis susceptibility increase. Also, DKA can lead to an acidemic state, allowing more free iron available for fungal growth and elevating the risk of mucormycosis co-infection.

3. Endothelialitis is another sequela of COVID-19 that might explain the risk of mucormycosis co-infection in COVID-19 patients. Endothelial damage facilitates angio-invasion and dissemination of mucormycosis. Additionally, COVID-associated low pH, hyperglycemia, and high iron levels contribute to the expression of glucose-regulator protein 78 (GRP-78) of endothelium cells and fungal ligand spore coating homolog (CotH) protein. These two receptors mediate the adhesion and penetration of mucorales into the tissues.

In addition to systemic corticosteroids, our studies described immunomodulatory drugs (such as tocilizumab) and voriconazole intake among their cases. In this matter, immunomodulatory drugs such as tocilizumab increased the co-infection susceptibility in one study. Also, published studies have demonstrated an increased risk of mucormycosis in patients who received voriconazole.

Some of our studies reported lymphoma, leukemia, and solid organ transplant cases in table. These observations are consistent with previous publications. Based on the existing evidence, malignancies, organ transplantation, and hemopathies are known risk factors for mucormycosis infection. Moreover, in an observational study by Patel et al, malignancy and organ transplant were the most significant risk factor after DM.

4.3 Target organs

Mucormycosis may target the nasal cavity, paranasal sinuses, orbit fossa, central nervous system (CNS), lung (pulmonary), gastrointestinal tract, skin, jawbones, joints, heart, kidney, and mediastinum. We observed similar findings to the systematic review by Singh et al that suggested nasal cavity and paranasal sinuses are the most common site of involvement (88.9%), followed by rhino-orbital involvement (56.7%). To determine the site of mucormycosis infection, several variables are important. For example, the site of involvement depends on the underlying cause of mucormycosis. Rhino-cerebral form of the infection is associated with uncontrolled DM and DKA, while the pulmonary form is associated with neutropenia, organ transplant, and hematological malignancies. Besides, critical lung damage in severe cases of COVID-19 might increase the risk of imposed pulmonary mucormycosis infection since mucormycosis can share an airborne route and primary pulmonary entry with COVID-19.

4.4 Mortality

As a rare invasive fungal infection, mucormycosis inflicts high morbidity and mortality on patients. In the COVID-19 setting, Singh et al reported a mortality rate of 30.7% in patients with COVID-19 and mucormycosis co-infection. This study comes very close to the 33.6% we found in this study. However, the lack of larger studies makes the reported rate unreliable. Since most of our studies were case reports consisting of only one patient, their mortality rates were either 0% or 100%. Subsequently, due to the diverse demographic backgrounds and features of the cases, combining their mortality rates seems inconclusive.

4.5 Diagnosis time

The early diagnosis of mycosis and pursuant treatment is crucial for a propitious outcome and prognosis. The mean day of diagnosis was 25.6 ± 21. A systematic review of 34 studies and 275 cases by Muthu et al reported the mean diagnosis time 19.5 days from COVID-19 onset. The Earliest times to diagnose mucormycosis infection in COVID-19 patients were reported on days 3, 14, 4, 19 and 6, respectively, in one, one, and two patients. In contrary, in four studies, it was diagnosed late; after 45 days in one patient, after 60 days in 33 patients, and after 90 days in one patient; the patient, who was diagnosed 90 days after the infection, had a heart transplant.

4.6 Co-infections

The most common co-infection of mucormycosis reported pulmonary invasive aspergillosis in COVID-19 patients, which raises concerns about increased mortality. Cases of mucormycosis and aspergillosis co-infection have been reported in hospitalized COVID-19 patients in two studies with the sample sizes of 36 and eight patients from Egypt, respectively, representing 30.6% and 12.5%. Also, this co-infection was reported in four case reports; two of which in France and the others in India and the United States. One study reported pericarditis in two patients. This finding was consistent with the findings of other systematic review studies; aspergillosis has been reported to be the most opportunistic concomitant infection in these studies.
4.7 | Treatment

The poor outcome of mucormycosis infections is rather dependent on the severe invasiveness, vigorous of the mycotic infections, and severe suppression of the immune system. The precise comprehensive treatment is radical debridement and incision of infected tissue, alongside therapy with high-dose amphotericin B. As expected, amphotericin B as the most common drug used for the management of COVID-19 patients with mucormycosis was observed in 92% of the cases. In addition, the use of antifungals has been reported regularly in studies, mostly voriconazole (17.3%). Also, for treatment of COVID-19, the use of hydroxychloroquine (18.5%), dexamethasone (16%), and tocilizumab (8.3%) were reported. The use of high-dose corticosteroids had been reported in most of the studies to manage COVID-19 disease; since the systematic steroids barricade the immune system as well as negatively affects glycemic control, its use should be further investigated.68 Other systematic review studies have also reported the use of corticosteroids in many cases of mucormycosis.67,69 Of the 144 patients studied in the surveys, more than half of them (52%) had debridement of infected tissue. Furthermore, 23.2% underwent mechanical ventilation due to respiratory problems caused by COVID-19. Proper actions to reduce the incidence of this fungal infection include early detection of patients with mucormycosis, the timely start of medical treatment and surgical operations to debride the infected tissue and proper and adequate use of corticosteroids in COVID-19 patients.

5 | LIMITATIONS

As the new coronavirus gained mainstream attention among infectious diseases, less and less attention has been given to fungal infections. Meanwhile, the diversity of COVID-19 symptoms overshadowed the other probable pathological conditions of COVID-19 patients, due to which the diagnosis of many fungal co-infections has been delayed. Thus, the relatively small number of published studies reporting mucormycosis co-infection in COVID-19 patients was the main limitation concerning the aim of this paper. In addition, the small sample size in each study and extreme mortality rates in case reports and case series hindered a comparison between the mortality rate of single COVID-19 infection and mucormycosis co-infection. Furthermore, most studies were case reports or small case series that may introduce biases to the study, for example, they may report specific circumstances that occur rarely in the real world but are emphasized in case reports.

6 | CONCLUSION

The mucormycosis co-infection in COVID-19 patients is of great concern as it raises mortality and delay diagnosis is probable in the setting of COVID-19. In addition, the lung involvement caused by the COVID-19 infection could often worsen by the mucormycosis fungal infection and the patient, therefore, has a higher risk of mortality or developing a serious medical condition. Furthermore, the diagnosis of mucormycosis co-infection plays an important role in determining the patient’s treatment plan, as corticosteroids, a treatment choice for COVID-19, is simultaneously a risk factor for mucormycosis infection. To manage both infections at the same time, one may consider debridement of the tissue infected with mucormycosis, mechanical ventilation, and proper use of corticosteroids, which could be a challenge in cases of mucormycosis co-infection; especially in critically ill patients with diffused lung involvement and receiving high doses of corticosteroids. To avoid the problems arising from mucormycosis, we should have the patients’ hyperglycemia under control and use corticosteroid only when needed, and suspect the clinical findings pointing to a mucormycosis co-infection earlier with the aim of a quicker diagnosis leading to a better prognosis.

Overall, we recommend considering the co-infection with mucormycosis when the patient’s symptoms do not completely match up with a single COVID-19 infection, especially in those receiving corticosteroids as COVID-19 treatment or else wise, patients with underlying co-morbidities such as diabetes and immunocompromised patients. Avoiding high-dose corticosteroids through the early stages of COVID-19 would also help to prevent mucormycosis co-infection. Finally, providing an early diagnosis of mucormycosis, through an adequate follow-up of patients, who have recently received corticosteroids as COVID-19 treatment, would give the physician an advantage in timely managing the patient.

ACKNOWLEDGMENTS

The present study was conducted in collaboration with Khalkhal University of Medical Sciences, Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran, Iran and Department of Global Health and Socioepidemiology, Kyoto University.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest

AUTHOR CONTRIBUTIONS

The conception and design of the study: Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi.
Methodology: Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi, Amirali Karimi.
Acquisition of data: Amirali Karimi, Alireza Barzegary, Zahra Pashaei.
Analysis and interpretation of data: Nazanin Janfaza, Alireza Shojaei, Fatemeh Afroughi, Parsa Mohammadi, Yasna Soleimani, Newsha Nazarian.
Writing—Original Draft Preparation: Amir Masoud Afsahi, Sanam Ailiou, Nazanin Janfaza, Alireza Shojaei, Fatemeh Afroughi, Parsa Mohammadi, Yasna Soleimani, Newsha Nazarian, Ava Amiri, Marcarious M. Tantuoyir, Shahram Oliaei.
Writing—Review and Editing: SeyedAhmad SeyedAlinaghi, Omid Dadras.
Validation: Esmaeil Mehraeen, Omid Dadras, SeyedAhmad SeyedAlinaghi.
All authors have read and approved the final version of the manuscript. Esmaeil Mehraeen had full access to all of the data in this study and takes complete responsibility for the integrity of the data.
TRANSPARENCY STATEMENT

Esmaeil Mehraeen affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

DATA AVAILABILITY STATEMENT

The authors confirm that the data supporting the findings of this study are available within the article.

ORCID

SeyedAhmad SeyedAlinaghi https://orcid.org/0000-0003-3210-7905
Alireza Barzegary https://orcid.org/0000-0002-0512-7014
Esmaeil Mehraeen https://orcid.org/0000-0003-4108-2973
Omid Dadras https://orcid.org/0000-0001-9385-2170

REFERENCES

1. Dadras O, Alinaghi SAS, Karimi A, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. *Eur J Med Res*. 2021;26(1):67.
2. SeyedAlinaghi S, Mirzapour P, Dadras O, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. *Eur J Med Res*. 2021;26(1):51.
3. SeyedAlinaghi S, Karimi A, MohseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. *Immun Inflam Dis*. 2021;9(4):1160-1185.
4. Oliaei S, SeyedAlinaghi S, Mehrbak M, et al. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review. *Eur J Med Res*. 2021;26(1):96.
5. SeyedAlinaghi S, Mehrbak M, MohseniPour M, et al. Genetic susceptibility of COVID-19: a systematic review of current evidence. *Eur J Med Res*. 2021;26(1):46.
6. SeyedAlinaghi S, Afsahi AM, MohseniPour M, et al. Late complications of COVID-19: a systematic review of current evidence. *Arch Acad Emerg Med*. 2021;9(1):e14.
7. Karimi A, Nowroozi A, Aliou S, Amini E. Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: a systematic review and meta-analysis. *Urol J*. 2021;18(6):577-584.
8. He S, Liu W, Jiang M, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. *PLoS One*. 2021;16(4):e0249668.
9. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral Mucormycosis and COVID-19 pneumonia. *J Med Cases*. 2021;12(3):85-89.
10. Arana C, Cuestas Ramirez RE, Xipeli M, et al. Mucormycosis associated with covid19 in two kidney transplant patients. *Transplant Infect Dis*. 2021;23(4):e12652.
11. Bayram N, Ozsayacli C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J Ophthalmol*. 2021;65(4):515-525.
12. Vesi A, Bagheri A, Eshghi M, Rikhteghar MH, Rezaei Kanavi M, Farjad R. Rhinocerebral mucormycosis during steroid therapy in COVID-19 patients: a case report. *Eur J Ophthalmol*. 2021;112067212110094.
13. Ashour MM, Abdelaaliz TT, Ashour DM, Askoura A, Saleh MI, Mahmoud MS. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. *J Neuroadiol*. 2021;48:319-324.
14. Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated Mucormycosis (CAM): case report and systematic review of literature. *Mycopathologia*. 2021;186(2):289-298.
15. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK Patients with severe fatal COVID-19: a postmortem study. *The Lancet Microbe*. 2020;16(2):e245-e253.
16. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. *Diabet Metab Syndrome*. 2021;15(4):102146.
17. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit (London)*. 2021;1-4.
18. do Monte ES, dos Santos MEL, Ribeiro IB, et al. Rare and fatal gastrointestinal Mucormycosis (Zygomycosis) in COVID-19 patient: a case report. *Clin Endoscopy*. 2020;53(6):746-749.
19. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Autoimmune rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. *Ophthal Plast Reconstr Surg*. 2021;37(2):e40-e80.
20. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. *Med Mycol Case Reports*. 2021;32:64-67.
21. El-Kholy NA, El-Fattah AMA, Khafagy YW. Invasive fungal sinusitis in post COVID-19 patients: a new clinical entity, Loryngoscope. 2021;131(12):2652-2658.
22. Bellanger AP, Navello JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient. *Infec Dis*. 2021;51:633-635.
23. Fekkar A, Lampros A, Mayaux J, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. *Am J Respir Crit Care Med*. 2021;203(3):307-317.
24. Buil JB, van Zanten ARH, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort S, et al. Case series of four secondary mucormycosis infections in COVID-19 patients; the Netherlands, December 2020 to May 2021. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021;26(23).
25. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of Rhizopus aszygoupeus pneumonia following COVID-19. *J Fungi (Basel, Switzerland)*. 2021;7(3):174.
26. Karimi Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol*. 2021;11:1029-1030.
27. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient – case report and review of literature. *Journal of. Med Mycol*. 2021;31(2):101125.
28. Krishna DS, Raj H, Kurup P, Jinee Y, Maiti Y, Ramaiah. Maxillofacial infections in Covid-19 era-actuality or the unforeseen: 2 case reports. *Journal of. Otolaryngol Head Neck Surgery*. 2021;1-4.
29. Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autopotic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. *JCases*. 2021;25:e01172.
30. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in COVID-19 patient: A case report. *Int J Surg Case Rep*. 2021;82:105957.
31. Mehta S, Pandey A. Rhino-orbital Mucormycosis associated with COVID-19. *Cureus*. 2020;12(9):e10726.
32. Rao R, Shetty AP, Nagesh CP. Orbital infection syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features. *Indian J Ophthalmol*. 2021;69(6):1627-1630.
33. Ravan SA, Agraval GA, Leuva PA, Modhi PH, Ahim KD. Rise of the phoenix: Mucormycosis in COVID-19 times. *Indian J Ophthalmol*. 2021;69(6):1563-1568.
34. Revannavar SM, Supriya P, Samaga L, Vineeth K. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? *BMJ Case Rep*. 2021;14(4):e241663.
35. Sarkar S, Gokhale T, Choudhury S, Deb A. COVID-19 and orbital mucormycosis. Indian J Otolaryngol Head Neck Surg. 2021;1-4.

36. Saldanha M, Reddy R, Vincent MJ. Title of the article: Paranasal SEYEDALINAGHI ET AL.

37. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Otolaryngol 2021;69(2): 244-252.

38. Waizel-Hait S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13(2):e13163.

39. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42: 264.e5-e8.

40. Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary Mucormycosis due to Rhizopus microsorus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel, Switzerland). 2021;7(2):88.

41. Bhattacharyya A, Sarma P, Sharma DJ, et al. Rhino-orbital-cerebral mucormycosis: a systematic review. Indian J Pharmacol. 2021;53(4):317-327.

42. Bala K, Chander J, Handa U, Punia RS, Attrri AK. A prospective study of mucormycosis in North India: experience from a tertiary care hospital. Med Mycol. 2015;53(3):248-257.

43. Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402.

44. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for Mucormycosis. J Fungi (Basel, Switzerland). 2021;7(4):298.

45. Goldman N, Fink D, Cai J, Lee YN, Davies Z. High prevalence of COVID-19-associated diabetic ketoacidosis in UKsecondary care. Diabetes Res Clin Pract. 2020;166:108291.

46. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian J Med Microbiol. 2021;39:380-383.

47. Sterne JAC, Murphy S, Diaz J V, et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341.

48. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1832-1838.

49. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.

50. Edeas M, Saleh J, Peyssonaux C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303-305.

51. Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hypertensive syndromes: the role of iron depletion therapy. Immunol Res. 2020;68(4):213-224.

52. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-199.

53. Kothankaraman N, Rengaraj A, Xue B, et al. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320(1):E139-e50.

54. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16-S22.

55. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395(10234):1417-1418.

56. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.

57. Balducci C, Ibrahim AS. Molecular mechanisms of mucormycosis-the bitter and the sweet. PLoS Pathog. 2017;13(8):e1006408.

58. Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: a case-control study. Life Sci. 2021;265:118781.

59. Kimmig LM, Wu D, Gold M, et al. IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020;7:583897.

60. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect. 2009;15(Suppl 5):93-97.

61. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405-e421.

62. Sugar AM. Mucormycosis. Clin Infect Dis. 1992;14(Suppl 1):S126-S129.

63. Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.e9-e15.

64. Prakash H, Chakrabarti A. Global epidemiology of Mucormycosis. J Fungi (Basel). 2019;5(1):26.

65. He F, Deng Y, Li W. Coronavirus disease 2019: what we know? J Med Virol. 2020;92(7):719-725.

66. Mutlu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(6):739-754.

67. Jose A, Singh S, Roychoudhury A, Kholakiya Y, Arya S, Roychoudhury S. Current understanding in the pathophysiology of SARS-CoV-2-associated rhino-Orbito-cerebral Mucormycosis: a comprehensive review. Journal of maxillofacial and Oral. Surgery. 2021;20:1-8.

68. Rodriguez-Morales AJ, Sah R, Millan-Oñate J, et al. COVID-19 Associated Mucormycosis: the Urgent Need to Reconsider the Indiscriminate Use of Immunosuppressive Drugs. London, England: SAGE Publications Sage UK; 2021.

69. Dilek A, Ozaras R, Ozkaya S, Sunbul M, Sen El, Leblebioglu H. COVID-19-associated mucormycosis: case report and systematic review. Travel Med Infect Dis. 2021;44:102148.

How to cite this article: SeyedAlinaghi S, Karimi A, Barzegary A, et al. Mucormycosis infection in patients with COVID-19: A systematic review. Health Sci Rep. 2022;5:e529. doi:10.1002/hsr2.529